Boothbay Fund Management Buys Stake in Dianthus Therapeutics

Institutional investor takes position in biotech company amid positive analyst sentiment

Mar. 16, 2026 at 7:52am

Got story updates? Submit your updates here. ›

Boothbay Fund Management LLC has purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), acquiring 138,963 shares valued at approximately $5.47 million. This represents around 0.32% ownership of the biotech company. The move comes amid positive analyst sentiment, with multiple firms upgrading their ratings and price targets on Dianthus Therapeutics.

Why it matters

Dianthus Therapeutics is a clinical-stage biotech company developing complement therapeutics for severe autoimmune and inflammatory diseases. The Boothbay Fund Management investment and positive analyst coverage suggest growing institutional interest and confidence in the company's pipeline and prospects.

The details

According to a recent 13F filing, Boothbay Fund Management purchased the 138,963 shares of Dianthus Therapeutics in the third quarter. This represents a new position for the investment firm in the biotech company. Dianthus Therapeutics is currently developing its lead candidate DNTH103, a monoclonal antibody in Phase 2 clinical trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

  • Boothbay Fund Management purchased the Dianthus Therapeutics shares in the third quarter of the year.

The players

Boothbay Fund Management LLC

An investment management firm that has taken a new position in Dianthus Therapeutics, acquiring 138,963 shares.

Dianthus Therapeutics, Inc.

A clinical-stage biotechnology company developing complement therapeutics for severe autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The Boothbay Fund Management investment and positive analyst sentiment around Dianthus Therapeutics suggest growing institutional confidence in the biotech company's pipeline and potential, despite ongoing cash burn and timing risks associated with its pre-profit, high-growth stage.